Salegio comes to ClearPoint Neuro with over 19 years of experience in translational neuroscience, including over 16 years of gene therapy experience working with adeno-associated viral vectors. The appointment is effective March 1.

ClearPoint Neuro launched its biologics and drug delivery team in 2020 to provide a range of services for pharmaceutical and academic partners working on gene and stem cell therapies for the brain, according to the firm.